Irritable bowel syndrome treatment Market 2025 Trends, Analysis, Market Forecast, Production Demand

Irritable bowel syndrome (IBS) is a gastrointestinal illness that mostly affects the large intestine. Abdominal pain, bloating, gas, cramps, and constipation or diarrhoea are all signs and symptoms. IBS is classified into three types: IBS with diarrhoea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. Irritable bowel syndrome treatment consists of stress reduction, dietary changes, appropriate medications, and counselling. Rifaximin, eluxadoline, lubiprostone, linaclotide, and other medications are available to treat irritable bowel syndrome. Furthermore, antispasmodics such as dicyclomine, peppermint oil, and hyoscyamine are used to treat irritable bowel syndrome.

The global irritable bowel syndrome treatment market was valued at US$ 726.1 million in 2016 and is expected to witness a robust CAGR of 12.9% over the forecast period (2017-2025).

The rise in the elderly population, the rise in the incidence of gastrointestinal diseases and disorders such as bowel habit changes and abdominal pain, the rise in stress levels, and an unhealthy diet are the primary reasons driving the growth of the irritable bowel syndrome treatment market. In addition, an increase in awareness initiatives regarding the treatment and management of irritable bowel syndrome, as well as an increase in predisposition toward IBS products that improve therapeutic outcome, are factors that contribute to the market's growth. Furthermore, the developing economies' untapped potential presents profitable chances for market expansion during the projection period. However, the lack of specialised treatments that treat all of the symptoms of IBS disease, as well as intense pricing competition among prominent providers, are projected to limit market expansion.

The market for irritable bowel syndrome treatment is classified by category, product, end user, and location. The market is divided into three types: IBS with diarrhoea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. The market is divided by product into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. The market is segmented into three segments based on end user: hospital pharmacies, drug shops & retail pharmacies, and online pharmacies. The irritable bowel syndrome therapy market is divided into four regions: North America, Europe, Asia-Pacific, and Latin America.